A Plethora of possibilities
Ok now that Lilly and Novo have reported we all knew what was obvious – they are just killing it and battling it out once again. The hype and hysteria over weight loss continues so much so that the Amgen call was dominated by a very early-stage obesity drug that may or may not ever make it to market. The hysteria extended to the fast-food executives who have been calling the Novo CEO worried that people will stop eating Fritos Doritos and potato chips.
Folks I’ll keep things very simple here – when it comes to the obesity . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.